ReviewCurrent opinion in cardiology2011
Effects of niacin on atherosclerosis and vascular function.
Review in Current opinion in cardiology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 36 citations in OpenAlex.
- High-density lipoproteins, Part 1. Epidemiology, antiatherogenic effects, and therapies designed to increase their serum levels.American journal of preventive cardiology · 2025Review
- Commentary on "Relationship between dietary niacin intake and erectile dysfunction: a population-based study".Asian journal of andrology · 2024Article
- Sirtuins in atherosclerosis: guardians of healthspan and therapeutic targets.Nature reviews. Cardiology · 2022Review
- Improved effect of a mitochondria-targeted antioxidant on hydrogen peroxide-induced oxidative stress in human retinal pigment epithelium cells.BMC pharmacology & toxicology · 2021Article
- The Absence of Adiponectin Alters Niacin's Effects on Adipose Tissue Inflammation in Mice.Nutrients · 2020Article
- A brief overview of currently used atherosclerosis treatment approaches targeting lipid metabolism alterations.American journal of cardiovascular disease · 2020Review
- Protective effects of lipoic acid-niacin dimers against blue light-induced oxidative damage to retinal pigment epithelium cells.International journal of ophthalmology · 2019Article
- Long-term consumption of energy drinks induces biochemical and ultrastructural alterations in the heart muscle.Anatolian journal of cardiology · 2018Article
- Local Inhibition of Macrophage and Smooth Muscle Cell Proliferation to Suppress Plaque Progression.Methodist DeBakey cardiovascular journal · 2016Review
- The role of nutrition and body composition in peripheral arterial disease.Nature reviews. Cardiology · 2012Review
- The role of nutraceutical supplements in the treatment of dyslipidemia.Journal of clinical hypertension (Greenwich, Conn.) · 2012Article
- Effects of paraoxonase activity and gene polymorphism on coronary vasomotion.EJNMMI research · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
purpose of reviewNiacin has been used for more than 50 years in the management of atherosclerosis and is associated with improved patient outcomes. The routine use of niacin has been superseded in recent years with the advent of newer lipid-modulating interventions. Recently, however, there has been a renewed interest in its use due to the appreciation of its many beneficial effects on atherosclerosis and endothelial function, both 'lipid-targeted' and 'pleiotropic'. This review will consider the effects of niacin in the setting of clinical trials and will critically evaluate proposed mechanisms of action. RECENT
findingsThe identification of the GPR109A receptor has promoted a greater insight into niacin's mechanism of action, with demonstrated beneficial effects on endothelial function and inflammation, in addition to its lipid modulation role. SUMMARY: Whether niacin itself is used routinely in the future will depend on the outcomes of two large outcome trials (AIM-HIGH and HPS2-THRIVE). In the future, however, with even better understanding of niacin pharmacology, new drugs may be able to be engineered to capture aspects of niacin that capitalize on the benefits more specifically and also more selectively, to avoid troublesome side-effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.